Ultragenyx Pharmaceutical (RARE) to Release Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.58) per share and revenue of $145.98 million for the quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded up $0.45 during trading on Friday, hitting $38.09. 575,372 shares of the company's stock traded hands, compared to its average volume of 818,321. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -6.01 and a beta of 0.61. Ultragenyx Pharmaceutical has a 12-month low of $29.59 and a 12-month high of $60.37. The business has a 50 day moving average of $37.79 and a 200-day moving average of $43.68.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Wedbush restated a "neutral" rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. JPMorgan Chase & Co. upped their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the transaction, the chief executive officer now directly owns 641,731 shares in the company, valued at $27,016,875.10. The trade was a 10.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 124,643 shares of company stock valued at $5,256,268. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.